Company Registration No. 02624214 (England and Wales)
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
COMPANY INFORMATION
Directors
CL Macau Jr
V Mendelson
(Appointed 5 February 2025)
D McGivern
(Appointed 5 February 2025)
Secretary
Mrs L Coppard
Company number
02624214
Registered office
HVT Centre
Rontgen Place
Great Notley
Braintree
Essex
CM77 7AX
Auditor
Rickard Luckin Limited
1st Floor
County House
100 New London Road
Chelmsford
Essex
CM2 0RG
Bankers
JP Morgan Chase and Co
19th Floor
25 Bank Street
London
E14 5JP
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 4
Independent auditor's report
5 - 8
Statement of comprehensive income
9
Balance sheet
10
Statement of changes in equity
11
Statement of cash flows
12
Notes to the financial statements
13 - 23
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 OCTOBER 2024
- 1 -
The directors present the strategic report for the year ended 31 October 2024.
Principal activities
The Company's principal activities during the year were the development, manufacture of and testing of high voltage interconnect systems. High voltage interconnection systems are found across a broad cross section of industrial, medical, commercial & scientific applications.
Review of the business
The Company's key financial performance indicators during the year were as follows:
2024 2023
£'000 £'000
Revenue 7,147 8,269
Operating Profit 2,190 2,784
Earnings Before Interest & Taxes (EBIT) 2,190 2,784
EBITDA 2,222 2,821
Average number of employees 50 56
This statement reflects a resilient performance in the face of significant and dynamic global events. Many new projects were undertaken in 2023 which resulted in an untypical record year. 2024’s revenue was more consistent with budget and previous years. Margin %’s remain consistent each year.
To support our strategic growth plans we continue to invest in construction of a new purpose designed 60,000 sq ft unit at the Horizon 120 Business and Innovation Park close to the A120 in Braintree, Essex. Project completion is scheduled for Spring 2025. This move will give us the capacity to undertake new projects which will increase revenue and profitability.
Principal risks and uncertainties
RISK & POTENTIAL EFFECT
MITIGATING ACTIONS
Global markets
Essex X-Ray's is subject to UK and global political and macro-economic conditions. A number of the Company's products are supplied for use into industries which are dependent upon, and subject to, government policies and national and international political considerations and budgetary constraints. Reduction in military spending or prolonged downturn due to recession or economic instability would adversely affect our sales.
• Increasing diversity of products through ongoing development of strategic growth application areas.
• Expanding geographical spread.
• Maintaining flexibility within the cost base to enable prompt response to significant changes in market conditions and demand.
• Strengthening sales management processes.
Advancement in technology
Essex X-Ray operates in competitive global markets characterised by continuous technological development which is integral to the Company's business of design and manufacture of specialist technology for high performance systems and equipment. Failure to innovate could result in our product offering becoming obsolete. The development of new technologies carries risks including failure to develop a commercially viable offering, taking longer to reach the market than planned and the risk that market size will be smaller than originally envisaged.
• Focusing research and development programmes on innovations consistent with the Company's strategic aims.
• Working closely with customers and to ensure the Company develops solutions tailored to their needs and involving them extensively during product development.
• Working closely with other companies in the Group to share technologies.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 2 -
D McGivern
Director
17 October 2025
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 OCTOBER 2024
- 3 -
The directors present their annual report and financial statements for the year ended 31 October 2024.
Results and dividends
The results for the year are set out on page 9.
Ordinary dividends were paid amounting to £769,847. The directors do not recommend payment of a final dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
CL Macau Jr
V Mendelson
(Appointed 5 February 2025)
D McGivern
(Appointed 5 February 2025)
Statement of directors' responsibilities
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Strategic report
The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of financial risk disclosures, future developments and subsequent events.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
Auditor
In accordance with the company's articles, a resolution proposing that Rickard Luckin Limited be reappointed as auditor of the company will be put at a General Meeting.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 4 -
Medium-sized companies exemption
This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.
On behalf of the board
D McGivern
Director
17 October 2025
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 5 -
Opinion
We have audited the financial statements of Essex X-Ray and Medical Equipment Limited (the 'company') for the year ended 31 October 2024 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 October 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 6 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Directors' Report.
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Capability of the audit in detecting irregularity, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our: general commercial and sector experience; through verbal and written communications with those charged with governance and other management; and via inspection of the company’s regulatory and legal correspondence.
We discussed with those charged with governance and other management the policies and procedures regarding compliance with laws and regulations.
We communicated identified laws and regulations to our team and remained alert to any indicators of non-compliance throughout the audit, we also specifically considered where and how fraud may occur within the company.
The potential effect of these laws and regulations on the financial statements varies considerably.
Firstly, the company is subject to laws and regulations that directly affect the financial statements, including: the company’s constitution, relevant financial reporting standards; company law; tax legislation and distributable profits legislation and we assess the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 7 -
Secondly the company is subject to many other laws and regulations where the consequences of non-compliance could have a material effect on the amounts or disclosures in the financial statements, for instance through the imposition of fines and penalties, or through losses arising from litigations. We identified the following areas as those most likely to have such an affect: employment legislation; health and safety legislation; data protection legislation; OFAC trading compliance; anti-bribery and anti-corruption legislation.
ISAs (UK) limit the required procedures to identify non-compliance with these laws and regulations, and no procedures over and above those already noted are required. These limited procedures did not identify any actual or suspected non-compliance with laws and regulations that could have a material impact on the financial statements.
In relation to fraud, we performed the following specific procedures in addition to those already noted:
Challenging assumptions made by management in its accounting estimates.
Identifying and testing journal entries, in particular any entries posted with unusual nominal ledger account combinations, journal entries crediting cash or any revenue account and large or unusual entries.
Performing analytical procedures to identify unexpected movements in account balances which may be indicative of fraud;
Ensuring that testing undertaken on both the performance statement, and the balance sheet includes a number of items selected on a random basis; and
Discussions with management;
These procedures did not identify any actual or suspected fraudulent irregularity that could have a material impact on the financial statements.
Throughout our audit work we have considered the entities internal control procedures, and the potential for fraudulent activity going undetected. We have concluded that the company's internal control procedures are adequate to mitigate the risk of material misstatement.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with ISAs (UK). For example, the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely the procedures that we are required to undertake would identify it. In addition, as with any audit, there remains a high risk of non-detection of irregularities, as these might involve collusion, forgery, intentional omissions, misrepresentation, or the override of internal controls. We are not responsible for preventing non-compliance with laws and regulations or fraud, and cannot be expected to detect non-compliance with all laws and regulations or every incidence of fraud.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
- 8 -
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Paul Forster (Senior Statutory Auditor)
For and on behalf of Rickard Luckin Limited
17 October 2025
Chartered Accountants
Statutory Auditor
1st Floor
County House
100 New London Road
Chelmsford
Essex
CM2 0RG
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 OCTOBER 2024
- 9 -
2024
2023
Notes
£
£
Turnover
3
7,146,682
8,268,784
Cost of sales
(4,104,747)
(4,683,359)
Gross profit
3,041,935
3,585,425
Administrative expenses
(851,696)
(801,684)
Operating profit
4
2,190,239
2,783,741
Interest payable and similar expenses
6
(283,970)
(51,653)
Profit before taxation
1,906,269
2,732,088
Tax on profit
7
(472,801)
Profit and total comprehensive income for the financial year
17
1,906,269
2,259,287
The profit and loss account has been prepared on the basis that all operations are continuing operations.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
BALANCE SHEET
AS AT 31 OCTOBER 2024
31 October 2024
- 10 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
9
11,337,893
4,925,757
Current assets
Stocks
10
1,076,433
1,184,110
Debtors
11
2,102,196
1,318,155
Cash at bank and in hand
365,627
705,330
3,544,256
3,207,595
Creditors: amounts falling due within one year
12
(9,167,992)
(3,347,925)
Net current liabilities
(5,623,736)
(140,330)
Total assets less current liabilities
5,714,157
4,785,427
Creditors: amounts falling due after more than one year
13
(1,100,904)
(1,308,596)
Net assets
4,613,253
3,476,831
Capital and reserves
Called up share capital
15
100
100
Profit and loss reserves
17
4,613,153
3,476,731
Total equity
4,613,253
3,476,831
These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.
The financial statements were approved by the board of directors and authorised for issue on 17 October 2025 and are signed on its behalf by:
D McGivern
Director
Company registration number 02624214 (England and Wales)
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2024
- 11 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 November 2022
100
2,849,111
2,849,211
Year ended 31 October 2023:
Profit and total comprehensive income
-
2,259,287
2,259,287
Dividends
8
-
(1,631,667)
(1,631,667)
Balance at 31 October 2023
100
3,476,731
3,476,831
Year ended 31 October 2024:
Profit and total comprehensive income
-
1,906,269
1,906,269
Dividends
8
-
(769,847)
(769,847)
Balance at 31 October 2024
100
4,613,153
4,613,253
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 OCTOBER 2024
- 12 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
21
704,635
3,301,060
Interest paid
(10,608)
(39,686)
Income taxes paid
(494,075)
(654,638)
Net cash inflow from operating activities
199,952
2,606,736
Investing activities
Purchase of tangible fixed assets
(6,445,872)
(2,445,619)
Proceeds from disposal of tangible fixed assets
4,220
Net cash used in investing activities
(6,441,652)
(2,445,619)
Financing activities
Proceeds from borrowings
6,671,844
1,400,000
Repayment of borrowings
(200,647)
Dividends paid
(769,847)
(1,631,667)
Net cash generated from/(used in) financing activities
5,901,997
(432,314)
Net decrease in cash and cash equivalents
(339,703)
(271,197)
Cash and cash equivalents at beginning of year
705,330
976,527
Cash and cash equivalents at end of year
365,627
705,330
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
- 13 -
1
Accounting policies
Company information
Essex X-Ray and Medical Equipment Limited is a private company limited by shares incorporated in England and Wales. The registered office is HVT Centre, Rontgen Place, Great Notley, Braintree, Essex, CM77 7AX.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Revenue from the sale of goods and services are recognised when the significant risks and rewards of ownership have passed to the buyer (usually on dispatch of the goods or provision of services), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
1.4
Research and development expenditure
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Land and buildings Freehold
Nil on land and 5% on buildings cost
Plant and machinery
20% on net book value
Fixtures, fittings & equipment
20% on net book value and 33.33% on computer cost
Motor vehicles
25% on net book value
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 14 -
No depreciation is charged against assets under construction until they are brought into use. At this point the asset will be transferred into a fixed assets category.
1.6
Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
1.7
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.8
Cash at bank and in hand
Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.
1.9
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 15 -
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors and loans from fellow group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 16 -
Other financial liabilities
Derivatives are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.10
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.
1.11
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
1
Accounting policies
(Continued)
- 17 -
1.12
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.13
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.14
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
It is the opinion of the Director that there are no significant judgements or estimates within these financial statements.
3
Turnover
2024
2023
£
£
Turnover analysed by class of business
Manufacture and sale of goods
7,146,682
8,268,784
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
3
Turnover
(Continued)
- 18 -
2024
2023
£
£
Turnover analysed by geographical market
United Kingdom
3,474,518
3,744,520
Rest of the World
925,123
1,230,822
Europe
2,747,041
3,293,442
7,146,682
8,268,784
4
Operating profit
2024
2023
Operating profit for the year is stated after charging/(crediting):
£
£
Exchange losses
67,953
33,597
Research and development costs
2,281
4,186
Fees payable to the company's auditor for the audit of the company's financial statements
19,900
15,600
Depreciation of tangible fixed assets
31,700
37,741
(Profit)/loss on disposal of tangible fixed assets
(2,184)
15
5
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Production
33
39
Directors
1
1
Administration
16
16
Total
50
56
Their aggregate remuneration comprised:
2024
2023
£
£
Wages and salaries
1,811,581
1,996,195
Social security costs
196,657
204,792
2,008,238
2,200,987
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 19 -
6
Interest payable and similar expenses
2024
2023
£
£
Interest on financial liabilities measured at amortised cost:
Interest payable to group undertakings
273,361
51,653
Other finance costs:
Other interest
10,609
283,970
51,653
7
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
558,212
Adjustments in respect of prior periods
(85,411)
Total current tax
472,801
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
1,906,269
2,732,088
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 22.50%)
476,567
614,720
Tax effect of expenses that are not deductible in determining taxable profit
71,040
17,266
Change in unrecognised deferred tax assets
123,982
(1,479)
Adjustments in respect of prior years
(85,411)
Effect of change in corporation tax rate
1,005
Capital allowances in excess of depreciation
(672,387)
Depreciation on assets not qualifying for tax allowances
798
939
R&D Expenditure Credit
(74,239)
Taxation charge for the year
-
472,801
8
Dividends
2024
2023
£
£
Total dividends
Interim paid
769,847
1,631,667
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 20 -
9
Tangible fixed assets
Land and buildings Freehold
Assets under construction
Plant and machinery
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 November 2023
2,593,751
2,684,048
451,581
167,638
12,439
5,909,457
Additions
6,433,378
8,190
4,304
6,445,872
Disposals
(35,495)
(35,495)
At 31 October 2024
2,593,751
9,117,426
424,276
171,942
12,439
12,319,834
Depreciation and impairment
At 1 November 2023
467,390
348,187
156,622
11,501
983,700
Depreciation charged in the year
5,517
21,907
4,043
233
31,700
Eliminated in respect of disposals
(33,459)
(33,459)
At 31 October 2024
472,907
336,635
160,665
11,734
981,941
Carrying amount
At 31 October 2024
2,120,844
9,117,426
87,641
11,277
705
11,337,893
At 31 October 2023
2,126,361
2,684,048
103,394
11,016
938
4,925,757
10
Stocks
2024
2023
£
£
Raw materials and consumables
1,032,961
1,072,689
Work in progress
10,165
17,880
Finished goods and goods for resale
33,307
93,541
1,076,433
1,184,110
11
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
851,363
1,042,045
Corporation tax recoverable
355,863
Amounts owed by group undertakings
481,494
2,561
Other debtors
373,301
232,388
Prepayments and accrued income
40,175
41,161
2,102,196
1,318,155
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 21 -
12
Creditors: amounts falling due within one year
2024
2023
Notes
£
£
Other borrowings
14
8,766,615
1,613,717
Trade creditors
22,647
1,032,596
Amounts owed to group undertakings
10,867
160,055
Corporation tax
138,212
Other taxation and social security
33,970
36,429
Accruals and deferred income
333,893
366,916
9,167,992
3,347,925
13
Creditors: amounts falling due after more than one year
2024
2023
Notes
£
£
Other borrowings
14
1,100,904
1,308,596
Amounts included above which fall due after five years are as follows:
Payable by instalments
219,766
449,212
14
Loans and overdrafts
2024
2023
£
£
Loans from group undertakings
9,867,519
2,922,313
Payable within one year
8,766,615
1,613,717
Payable after one year
1,100,904
1,308,596
Included within amounts payable within one year is a balance of £8,319,424, which relates to the amount drawn down on a loan facility to fund the purchase of the company’s new factory. Once this loan is fully drawn down, its repayment terms will be formalised and a proportion of the debt would then be categorised as being due after one year.
15
Share capital
2024
2023
£
£
Ordinary share capital
Issued and fully paid
100 ordinary shares of £1 each
100
100
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 22 -
16
Financial commitments, guarantees and contingent liabilities
The company's bankers have provided a financial guarantee of £80,000 to HM Revenue and Customs. The company has not provided any specific security with respect to this guarantee.
17
Profit and loss reserves
All profit and loss reserves are distributable.
18
Ultimate controlling party
The immediate parent company is HVT Group Inc. and the ultimate undertaking and controlling party is HEICO Corporation, both of which are registered in the USA. The only company in which the results of Essex X-Ray and Medical Equipment Limited are consolidated is HEICO Corporation. Copies of the consolidated financial statements of HEICO Corporation can be obtained from the company secretary at 3000 Taft Street, Hollywood, FL 33021.
19
Operating lease commitments
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
2024
2023
£
£
Within one year
19,992
16,500
Between two and five years
18,930
33,000
38,922
49,500
20
Related party transactions
At the balance sheet date the company owed £10,867 (2023: £160,055) to a fellow subsidiary. At this date the company was also owed £2,013 by this fellow subsidiary and owed £7,098 (2023: £2,561) by the ultimate parent company.
In addition, during 2021 the company was loaned £2,100,000 by the ultimate parent company for the purchase of land. This loan is repayable over 10 years and interest is charged at a commercial rate. As at 31 October 2024 £1,548,095 (2023: £1,510,346) was the balance outstanding.
During 2023 the company was provided a second loan by the ultimate parent company for the construction of the new building. Up to £10,000,000 can be taken under this loan, and the amount drawn is repayable on demand. Interest is charged at a commercial rate. As at 31 October 2024 £8,319,424 (2023: £1,411,967) was the balance outstanding.
ESSEX X-RAY AND MEDICAL EQUIPMENT LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
- 23 -
21
Cash generated from operations
2024
2023
£
£
Profit after taxation
1,906,269
2,259,287
Adjustments for:
Taxation charged
472,801
Finance costs
283,970
51,653
(Gain)/loss on disposal of tangible fixed assets
(2,184)
15
Depreciation and impairment of tangible fixed assets
31,700
37,741
Movements in working capital:
Decrease/(increase) in stocks
107,677
(145,249)
Increase in debtors
(428,178)
(374,867)
(Decrease)/increase in creditors
(1,194,619)
999,679
Cash generated from operations
704,635
3,301,060
22
Analysis of changes in net debt
1 November 2023
Cash flows
Other non-cash changes
31 October 2024
£
£
£
£
Cash at bank and in hand
705,330
(339,703)
-
365,627
Borrowings excluding overdrafts
(2,922,313)
(6,671,844)
(273,362)
(9,867,519)
(2,216,983)
(7,011,547)
(273,362)
(9,501,892)
2024-10-312023-11-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.200CL Macau JrV MendelsonD McGivernMrs L Coppard026242142023-11-012024-10-3102624214bus:Director12023-11-012024-10-3102624214bus:Director22023-11-012024-10-3102624214bus:Director32023-11-012024-10-3102624214bus:CompanySecretary12023-11-012024-10-3102624214bus:RegisteredOffice2023-11-012024-10-3102624214bus:Agent12023-11-012024-10-31026242142024-10-31026242142022-11-012023-10-3102624214core:RetainedEarningsAccumulatedLosses2022-11-012023-10-3102624214core:RetainedEarningsAccumulatedLosses2023-11-012024-10-31026242142023-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2024-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2024-10-3102624214core:PlantMachinery2024-10-3102624214core:FurnitureFittings2024-10-3102624214core:MotorVehicles2024-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2023-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2023-10-3102624214core:PlantMachinery2023-10-3102624214core:FurnitureFittings2023-10-3102624214core:MotorVehicles2023-10-3102624214core:ShareCapital2024-10-3102624214core:ShareCapital2023-10-3102624214core:RetainedEarningsAccumulatedLosses2024-10-3102624214core:RetainedEarningsAccumulatedLosses2023-10-3102624214core:ShareCapital2022-10-3102624214core:RetainedEarningsAccumulatedLosses2022-10-3102624214core:ShareCapitalOrdinaryShareClass12024-10-3102624214core:ShareCapitalOrdinaryShareClass12023-10-31026242142023-10-31026242142022-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2023-11-012024-10-3102624214core:PlantMachinery2023-11-012024-10-3102624214core:FurnitureFittings2023-11-012024-10-3102624214core:MotorVehicles2023-11-012024-10-310262421412023-11-012024-10-310262421412022-11-012023-10-3102624214core:UKTax2023-11-012024-10-3102624214core:UKTax2022-11-012023-10-310262421422023-11-012024-10-310262421422022-11-012023-10-3102624214core:LandBuildingscore:OwnedOrFreeholdAssets2023-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2023-10-3102624214core:PlantMachinery2023-10-3102624214core:FurnitureFittings2023-10-3102624214core:MotorVehicles2023-10-3102624214core:ConstructionInProgressAssetsUnderConstruction2023-11-012024-10-3102624214core:CurrentFinancialInstruments2024-10-3102624214core:CurrentFinancialInstruments2023-10-3102624214core:Non-currentFinancialInstruments2024-10-3102624214core:Non-currentFinancialInstruments2023-10-3102624214bus:OrdinaryShareClass12023-11-012024-10-3102624214bus:OrdinaryShareClass12024-10-3102624214core:WithinOneYear2024-10-3102624214core:BetweenTwoFiveYears2024-10-3102624214bus:PrivateLimitedCompanyLtd2023-11-012024-10-3102624214bus:FRS1022023-11-012024-10-3102624214bus:Audited2023-11-012024-10-3102624214bus:FullAccounts2023-11-012024-10-31xbrli:purexbrli:sharesiso4217:GBP